Inozyme Pharma, Inc. (INZY)

Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)

4.000

0.00 (0.00%)

Inactive · Last trade price on Jun 30, 2025

Inozyme Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Market Capitalization	260	178	263	42	161	482	Upgrade
Market Cap Growth	-87.64%	-32.37%	520.31%	-73.72%	-66.55%	-	Upgrade
Enterprise Value	222	93	105	-92	40	323	Upgrade
Last Close Price	4.00	2.77	4.26	1.05	6.82	20.64	Upgrade
PB Ratio	8.17	3.08	1.87	0.36	1.48	3.05	Upgrade
P/TBV Ratio	8.17	3.08	1.87	0.36	1.48	3.05	Upgrade
Debt / Equity Ratio	1.48	0.81	0.33	0.06	0.03	-	Upgrade
Quick Ratio	1.98	3.35	12.87	8.70	9.62	14.83	Upgrade
Current Ratio	2.19	3.56	13.36	8.93	9.91	15.14	Upgrade
Return on Equity (ROE)	-141.69%	-102.90%	-54.98%	-58.91%	-42.36%	-55.64%	Upgrade
Return on Assets (ROA)	-48.45%	-40.13%	-27.81%	-32.67%	-24.17%	-32.81%	Upgrade
Return on Capital (ROIC)	-53.98%	-44.57%	-30.28%	-36.10%	-26.15%	-35.16%	Upgrade
Earnings Yield	-41.10%	-57.33%	-27.05%	-158.11%	-35.08%	-11.70%	Upgrade
FCF Yield	-37.18%	-51.68%	-26.98%	-137.15%	-30.08%	-7.58%	Upgrade
Buyback Yield / Dilution	-12.57%	-21.17%	-37.27%	-60.30%	-113.46%	-832.81%	Upgrade

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q